- 3.2 c after years of "development"- existing approvals, but no...

- 3.2 c after years of "development"
- existing approvals, but no strong promising revenue increase
- no promising cornerstone private market investor as far as I know
- baby app will fail (imo)
- no promising daily turnover
- no insider buying (do they keep the cash in the knowing that a CR is due agin soon?)
- not enough daily turnover, very low. Showing that nearly nobody is interested
- lets not forget the heavy mgt selling a few years ago.
- FDA matter could surprise negatively. Let apart first revenues aftern an approval (why? Look at SP and SP action)
- etc

very long list of selling reasons. But i wont sell. The shares are just there to be there. Probably
like many other share holders. But I believe to know that one day they are worthless.

all IMO